BioFocus, Almac Partner to Offer Screening, Profiling Services | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – BioFocus and Almac today announced a deal to provide compound screening and profiling services based on Almac's Flexyte fluorescence lifetime assays to BioFocus' customers.

BioFocus has launched an FLT screening and profiling service using the Flexyte assay platform and is offering services against targets such as proteases, phosphatases, and kinases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.